Biosense Webster, Medtronic Forge United Front Against Arrhythmias
May 9, 2007 — Biosense Webster Inc., a worldwide leader in cardiac mapping and ablation, and Medtronic Inc., world leader in implanted cardiac rhythm devices, have announced plans to collaborate on a clinical trial, educational initiatives and a product development program, all of which are aimed at advancing the care of patients with cardiac arrhythmias, also known as irregular heartbeats.
The initiative was announced Monday to coincide with the start of Heart Rhythm 2007, the Heart Rhythm Society's 28th Annual Scientific Sessions, taking place in Denver May 9-12. Heart Rhythm 2007 is the premier medical and scientific conference for electrophysiologists.
Under the terms of the agreement, the two companies plan to collaborate on three key areas of interest — a clinical trial, a technology development initiative and educational programs. The companies intend to design the clinical trial to create a new care pathway for identifying candidates most likely to have a successful ablation treatment outcome and increase the acceptance of ablation therapy.
In addition, the two companies will work together to advance patient care through a joint research and development program. The companies plan to integrate specific technologies to provide novel, new solutions for the treatment of complex cardiac arrhythmias.
For more information visit www.medtronic.com and www.biosensewebster.com.
More like this
- Biosense Webster Forges Big-Name Alliances
- Biosense Webster Reports Compelling Effectiveness of Force Sensing Thermocool Smartouch Catheter
- New Software, Catheter Enable Faster 3-D Mapping, Ablation
- Diagnostic EP Catheters, Ablation Devices See Strong Industry Growth
- FDA Grants Marketing Approval to NaviStar ThermoCool Catheter for Atrial Fibrillation